Carlos Acebal
Overview
Explore the profile of Carlos Acebal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
148
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aparicio C, Acebal C, Gonzalez-Vallinas M
Exp Hematol Oncol
. 2023 Aug;
12(1):73.
PMID: 37605218
Chimeric antigen receptor (CAR)-T cell therapy is one of the most promising advances in cancer treatment. It is based on genetically modified T cells to express a CAR, which enables...
2.
Franco E, Mateos A, Acebal C, Fernandez-Ortiz A, Sanchez-Brunete V, Garcia-Rubira J, et al.
Rev Port Cardiol
. 2014 Sep;
33(9):545-53.
PMID: 25216540
Introduction And Objectives: Current clinical guidelines for ST-segment elevation myocardial infarction (STEMI) suggest prehospital activation of the cardiac catheterization team. In previous protocols in our center activation occurred once patients...
3.
Ibanez B, Macaya C, Sanchez-Brunete V, Pizarro G, Fernandez-Friera L, Mateos A, et al.
Circulation
. 2014 Jul;
130(3):e19-20.
PMID: 25024129
No abstract available.
4.
Ibanez B, Macaya C, Sanchez-Brunete V, Pizarro G, Fernandez-Friera L, Mateos A, et al.
Circulation
. 2013 Sep;
128(14):1495-503.
PMID: 24002794
Background: The effect of β-blockers on infarct size when used in conjunction with primary percutaneous coronary intervention is unknown. We hypothesize that metoprolol reduces infarct size when administered early (intravenously...
5.
Ibanez B, Fuster V, Macaya C, Sanchez-Brunete V, Pizarro G, Lopez-Romero P, et al.
Am Heart J
. 2012 Oct;
164(4):473-480.e5.
PMID: 23067904
Background: Infarct size predicts post-infarction mortality. Oral β-blockade within 24 hours of a ST-segment elevation acute myocardial infarction (STEMI) is a class-IA indication, however early intravenous (IV) β-blockers initiation is...